Mobile

An open-label, non-randomized, sequential, multicenter study to evaluate the pharmacokinetics, efficacy and safety of once daily dosing compared to twice daily dosing of Orfadin in patients diagnosed ...

Update Il y a 4 ans
Reference: EUCTR2013-004132-29

An open-label, non-randomized, sequential, multicenter study to evaluate the pharmacokinetics, efficacy and safety of once daily dosing compared to twice daily dosing of Orfadin in patients diagnosed with hereditary tyrosinemia type 1

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the steady-state exposure to nitisinone during once and twice daily dosing of Orfadin

Inclusion criteria

  • hereditary tyrosinemia type 1

Links